References
- Knoelker U, Mattejat F, Schulte-Markwort M. I6Pder-und Jugendpsychiatrie und-psychotherapie. Uni-Med, Bremen, Germany (2000).
- Schweitzer J. Therapie dissozialer Jugendlicher Juventa, Weinheim, Germany (1987)
- Remschmidt H, Schulz E, Martin M, Fleischhaker C, Trott GE. Frahmanifestation schizophrener Psychosen. Zeitschrift fur Kinder- undJugendpsychiatrie 22 (4), 239–252 (1997).
- Nicolson R, Rapoport JL. Childhood- onset schizophrenia: rare but worth studying. Biol. Psychiatry46,1418–1428 (1999).
- Mattejat F, Remschmidt H. Aufgaben und Probleme der Qualitatssicherung in der Psychiatrie und Psychotherapie des Kindes- und Jugendalters. Kinder- und Jugendpsychiat23, 71–83 (1995).
- Campbell M, Cohen IL, Anderson LT Pharmacotherapy for autistic children, asummary of research. Can. J. Psychiatry 26,265–273 (1951).
- Campbell M, Fish B, David R, Shapiro T, Collins P, Koh C. Response to trijodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J. Autism Child Schizophr 2, 943–955 (1972).
- Jaselskis CA, Cook EH, Fleteher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder J. Clin. PTchopharm. 5, 322–327 (1992).
- Hunt R, Minderaa R, Cohen D. Clonidine benefits children with attention deficit disorder and hyperactivity: report of double-blind placebo crossover therapeutic trial. jAm. Acad. Child PFidatry24, 617— 629 (1955).
- Birmaher B, Quintana H, Greenhill LL. Methylphenidate treatment of hyperactive autistic children. jAm. Acad. Child Adoles. PTchiatry27, 248–251 (1988).
- Perry R, Campbell M, Adams P, Lyneh N, Speneer EK. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. jAm. Acad. Child Adoles. PFidatry25, 57–92 (1959).
- Campbell M, Adams P, Perry R, Speneer RK, Overall JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. PTchopharmacol Bull 24,251–255 (1985).
- Weizman A, Weizman R, Szekely GA etal Abnormal immune response to brain tissue antigen in the syndrome of autism. Arn. I Psych. 139,1462–1465 (1982).
- Stubbs EG, Crawford ML, Burger DL eta]. Depressed lymphocyte responsiveness in autistic children. j Autism Child Schizophr 7,49–55 (1977).
- Warren RP, Margaretten NC, Foster A. Reduced natural killer cell activity in autism. jAm. Acad. Child Adolesc. Psychol. 26,333–335 (1987).
- Yonk LI, Warren RP, Burger RA et al. CD4+ helper T cell depression in autism. Immunol. Lett. 25,341-345 (1990).
- Warren RP, Yonk LJ, Burger RA et al Deficiency of suppressorinducer T-cells in autism. Immunol Invest. 19,245–251 (1990).
- Warren RP, Margaretten NC, Pace NC etal Immune abnormalities in patients with autism. J. Autism Dev. Disoml 16, 189–197 (1986).
- Todd R, Ciaranello R. Demonstration of inter- and intra- species differences in serotonin binding sites by antibodies from an autistic child. Proc. Natl Acad. Li. USA 82,612–616 (1985).
- Fudenberg IIf I, Singh VK, Emerson D etal Immunodiagnosis and immunotherapy in autistic children. J. Neuroimmunol 16,58–59 (1987).
- Jannsen. Reminyl tablets prescribing information. Janssen Pharmaceutica, NV, USA (2000).
- Thomsen T, Kewitz H, Pleul O. Estimation of cholinesterase activity in undiluted plasma and erytrocytes as a tool for measuring in vivo effects of reversible inhibitors. j Clin. Chem. Clin. Biochem. 26,469–475 (1988).
- Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galantamine in vitro and in vivo. Life Sci. 46, 1553–1558 (1990).
- Chopin B, Briley M. Effects of four noncholinergic cognitive enhancers in comparison with tacrine and galantamine on scopolamine-induced amnesia in rats. P9rhopharmacology 106, 26–30 (1999).
- Bickel U, Thomsen T Weber W Pharmacoldnetics of galantamine in humans and corresponding cholinesterase inhibition. Clin. Phalmacol. 72n 50, 420–428 (1991).
- Bonner LT, Peskind ER. Pharmacologic treatments of dementia. Med. Gun. North Am. 86, 657–674 (2002).
- Howard AK, Thornton AE, Altman S, Honer WG. Donepezil for memory dysfunction in schizophrenia. Psychopharmacol. 16, 167–170 (2002).
- Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations: a case series. CI.117: Med. Res. Opin. 18, 258–264 (2002).
- Niederhofer H, Staffen W Mair A. Galantamine: modestly effective in treating children with autistic disorder BE Med (2003) (In Press).